Patents for A61P 35 - Antineoplastic agents (221,099)
01/2006
01/04/2006CN1234700C Taxone bromated analog with anticancer activity and preparation method thereof
01/04/2006CN1234698C Nitric oxide donors based on metallic centers
01/04/2006CN1234696C Taxad alkyl derivative and its prepn. process
01/04/2006CN1234693C Indazol compound for inhibiting protein kinase and medicine composition and their application
01/04/2006CN1234688C 3-arylindole and their use as cb2 receptor agonists
01/04/2006CN1234416C Compositions for sustained delivery of hydrophobic drugs and process for preparation thereof
01/04/2006CN1234413C Synergistic composition and its use
01/04/2006CN1234411C Anti-tumor medicine
01/04/2006CN1234408C Chinese medicine preparation for treating AIDS and preventing cancer
01/04/2006CN1234376C Rosa roxburghii bee jelly anti-cancer honey milk
01/04/2006CN1234369C Bacillus prodigiosus polysaccharide for nose drops
01/04/2006CN1234366C Use of active vitamin D analogue in preparing medicine for treating hyperproliferative diseases
01/04/2006CN1234363C Freezing-dried composition contg. dexrazoxane and its prepn. method
01/04/2006CN1234353C Application of gallic acid in prepn. of medicine for antitumor
01/03/2006US6982351 Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor
01/03/2006US6982333 Intermediates in the synthesis of camptothecin and related compounds and synthesis thereof
01/03/2006US6982320 Cytokine receptor common gamma chain like
01/03/2006US6982319 Protein for use in the treatment of liver disorders, fibrosis, cancer, rheumatoid arthritis and glomeronephritis
01/03/2006US6982282 Emulsion vehicle for poorly soluble drugs
01/03/2006US6982280 cytostaticum for example; use as medicaments and plant protection agents; synthetic methods which include a Suzuki coupling or a silent coupling (stille Kupplung)
01/03/2006US6982277 Antitumor agents, antiinflammatory agents; for example 2-(2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3(2H)-yl)-1-(4-methylphenyl) -1-ethanone, 2-(4-methylphenyl)-5,6,7,8-tetrahydrobenzo(d)-imidazo(2,1-b)thiazole
01/03/2006US6982276 Polymorphs of an epothilone analog
01/03/2006US6982270 1-Phenyl-2-oxo-3,4-dihydro-6-phenylaminoquinazoline for example; cytokine suppressive anti-inflammatory drugs; combination therapy
01/03/2006US6982266 N-(4-indol-5-yloxyphenyl){4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}carboxamide for example; antiproliferative agents which inhibit phosphorylation of kinases such as tyrosine kinase; cancer, arteriosclerosis
01/03/2006US6982265 Pyrrolotriazine inhibitors of kinases
01/03/2006US6982263 Peptidyl carbamates; treatments for osteoporosis and autoimmune diseases
01/03/2006US6982261 A progesterone receptor antagonist for providing progestational therapy, treating cancer of breast, uterine, ovarian, endometrial, or prostate, providing contraceptives, hormone replacement therapy
01/03/2006US6982259 N-heterocyclic derivatives as NOS inhibitors
01/03/2006US6982258 Low-calcemic oxime analogs of 1α,25-dihydroxy vitamin D3
01/03/2006US6982255 Comprises coadministration of galactomannan and chemotherapeutic agent (adriamycin)
01/03/2006US6982253 Liquid formulation of decitabine and use of the same
01/03/2006US6982096 Determining a therapeutic dosage of arsenic trioxide based upon the predetermined weight of the patient and administering; Leukemia; lymphomas; solid tumors; anticarcinoma and -tumor agents
01/03/2006US6982091 Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
01/03/2006CA2329005C Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
01/03/2006CA2264901C Association of no syntase inhibitors with trappers of oxygen reactive forms
01/03/2006CA2237897C 25-hydroxy-16-ene-26,27-bishomo-cholecalciferols
01/03/2006CA2187449C Anti-cancer compounds containing cyclopentaquinazoline ring
01/03/2006CA2185350C Acridone-derived bisintercalators as chemotherapeutic agents
01/03/2006CA2158937C Recombinant alphavirus vectors
01/03/2006CA2156289C Drug composition containing nucleic acid copolymer
01/03/2006CA2136622C Phosphotriester-type biologically active compounds
01/03/2006CA2135708C Vitamin d3 analogs
01/01/2006CA2512493A1 Methods for assessing and treating cancer
12/2005
12/29/2005WO2005123935A1 Method of producing therapeutically useful product and system
12/29/2005WO2005123908A2 Novel cancer cell lines and uses thereof
12/29/2005WO2005123769A1 Hla-a2-binding protein originating in prostate-related antigen
12/29/2005WO2005123767A1 Peptide-based compounds
12/29/2005WO2005123736A1 Novel 2-benzylaminodihydropteridinones, method for producing them and use thereof as drugs
12/29/2005WO2005123642A1 Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
12/29/2005WO2005123122A1 Peptide vaccine for cancer therapy
12/29/2005WO2005123120A1 Sustained release vaccine composition
12/29/2005WO2005123115A1 Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
12/29/2005WO2005123078A1 Liposome preparation containing slightly water-soluble camptothecin
12/29/2005WO2005055939A3 Vinca derivatives
12/29/2005WO2004082631A3 METHODS FOR PREPARATION AND USE OF 1α,24(S)-DIHYDROXYVITAMIN D2
12/29/2005WO2004074437A3 Compositions and methods for cancer immunotherapy
12/29/2005WO2004058191A3 Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
12/29/2005WO2004034965A3 Method for treating cancer
12/29/2005WO2003071933A3 Novel compositions and methods for cancer
12/29/2005WO2003012122A3 Crystallized structure of type iv collagen nc1 domain hexamer
12/29/2005WO2002099040A3 Igs as modifiers of the p53 pathway and methods of use
12/29/2005US20050289660 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
12/29/2005US20050289658 System for regulating in vivo the expression of a transgene by conditional inhibition
12/29/2005US20050288514 Desorption from synthetic resin with a weakly polar or apolar solvent; and separation of epothilones A and B by reversed-phase chromatography after being taken up in a suitable solvent and elution with a mixture of nitrile and water; desolventizing; crylstallization; industrial scale; efficiency
12/29/2005US20050288501 Reducing a 2-(protected amino)-3-(piperazin-1-yl, N-morpholinyl, or N-thiomorpholinyl) propanoate, deprotecting the amine, and reacting with t-butylisothiocyanate
12/29/2005US20050288492 Anti-activated RAS antibodies
12/29/2005US20050288368 Compositions and methods for treating and preventing necrosis
12/29/2005US20050288363 Therapeutic compositions and methods of use
12/29/2005US20050288356 Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics
12/29/2005US20050288353 Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
12/29/2005US20050288350 Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin
12/29/2005US20050288349 Cancer treatments and pharmaceutical compositions therefor
12/29/2005US20050288337 Novel compounds
12/29/2005US20050288332 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2ylmethyl)piperidin-4-yl]-1h- pyrrole mono-hydrochloride
12/29/2005US20050288327 Small molecule inhibitors of HER2 expression
12/29/2005US20050288324 Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
12/29/2005US20050288320 Induce biosymthesis of cytokines, interferons, tumor necrosis factor; antitumor agents; viricides; chemical intermediates
12/29/2005US20050288318 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics
12/29/2005US20050288313 Synergistically combined with immunomodulators or antiinflammtory agents; treating rheumatoid arthritis; inhibiting organ transplant rejection; Janus Kinase 3 inhibitors such as CP 690550, 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile
12/29/2005US20050288311 2-(dipropylamino)-8-(4-thiomorpholinyl)pyrido[3,4-d]pyrimidin-4(3H)-one; kianses inhibitor; anticarcinlgenic, antidiabetic, antiinflammatory, hypotensive agent; nontoxic
12/29/2005US20050288303 Cyclic protein tyrosine kinase inhibitors
12/29/2005US20050288297 {4-[6-methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl]piperazinyl}-N-[4-(methylethoxy)phenyl]carboxamide; inhibits phosphorylation of platelet-derived growth factor receptor to hinder abnormal cell growth/wandering; cancer; arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis
12/29/2005US20050288287 Chiral cis-imidazolines
12/29/2005US20050288285 Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
12/29/2005US20050288262 such as 3,10-Dibenzyloxyminocycline, used to treat bacterial infections and neoplasms, as well as blocking tetracycline efflux and modulation of gene expression
12/29/2005US20050288230 Non-steroidal anti-androgen therapy
12/29/2005US20050288211 Chemokine inhibitors; for treatment of gout; for inhibiting migration of neutrophils involved in pathogenesis
12/29/2005US20050287617 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
12/29/2005US20050287546 Novel proteases
12/29/2005US20050287530 TCL-1b gene and protein and related methods and compositions
12/29/2005US20050287521 Oligonucleotides from sequences coding for the surface component of ptlv envelope proteins and uses thereof
12/29/2005US20050287225 Metal cluster nano-compounds for treating tumor diseases
12/29/2005US20050287189 Antitumor, anticancer agents; particles or coils or stents coated solid-phase agent comprising a binding agent comprising collagen are directed to target vasculature, such as the vasculature of solid tumor masses or aneurysms
12/29/2005US20050287162 Recombinant fowlpox virus
12/29/2005US20050287160 Useful for treatment and prevention of prostate cancer, especially when associated with bone metastases; also a cytotoxic T lymphocyte that specifically recognizes complex of HLA-A24 antigen and the cancer antigen peptide
12/29/2005US20050287157 Dry formulation for transcutaneous immunization
12/29/2005US20050287145 Compositions and methods for producing vascular occlusion
12/29/2005US20050287144 For the modulation of signal activities controlled by NF-kappa B-inducing kinase (NIK); cancer , rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, asthma, cardiac infarct, Alzheimer's disease, or atherosclerosis
12/29/2005US20050287123 DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
12/29/2005DE112004000207T5 Organische Arsonsäureverbindungen Organic Arsonsäureverbindungen